These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6861348)

  • 1. Effect of Fluosol-DA on radioimmunoassay results.
    Hammarstrom M; Mullins R; Sgoutas D
    Clin Chem; 1983 Jul; 29(7):1418-21. PubMed ID: 6861348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell substitutes and artificial blood.
    Bowman RJ
    Hum Pathol; 1983 Mar; 14(3):218-20. PubMed ID: 6832769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Fluosol-DA (artificial blood) on clinical chemistry tests and instruments.
    Mullins RE; Hutton PS; Conn RB
    Am J Clin Pathol; 1983 Oct; 80(4):478-83. PubMed ID: 6624711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine kinetics following partial blood exchange with Fluosol-DA in the rat.
    Shrewsbury RP; White SG; Pollack GM; Wargin WA
    J Pharm Pharmacol; 1986 Dec; 38(12):883-7. PubMed ID: 2880960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of Fluosol-DA in acute cerebral ischemia.
    Peerless SJ; Ishikawa R; Hunter IG; Peerless MJ
    Stroke; 1981; 12(5):558-63. PubMed ID: 6795765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
    Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
    Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental studies on fluosol DA administration in acute pancreatitis.
    Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a perfluorocarbon emulsion (Fluosol-DA) on reticuloendothelial system clearance function.
    Castro O; Nesbitt AE; Lyles D
    Am J Hematol; 1984 Jan; 16(1):15-21. PubMed ID: 6695906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute.
    Lane TA; Lamkin GE
    Blood; 1986 Aug; 68(2):351-4. PubMed ID: 3524707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfluorocarbon emulsion prevents eicoasanoid release in skeletal muscle ischemia and reperfusion.
    Gennaro M; Mohan C; Ascer E
    Cardiovasc Surg; 1996 Jun; 4(3):399-404. PubMed ID: 8782946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%) on cerebral circulation in the monkey.
    Nagasawa S; Handa H; Naruo Y; Oda Y; Yonekawa Y; Takebe Y
    Neurol Res; 1981; 3(3):237-50. PubMed ID: 6122175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a perfluorochemical emulsion on the rat hepatic mixed function oxidase system.
    Ravis WR; Ramakanth S; Brzozowski DM; Hamrick ME
    J Pharm Pharmacol; 1992 Mar; 44(3):219-23. PubMed ID: 1354727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a perfluorocarbon emulsion, Fluosol-DA, on rat lymphoid tissue and immunological competence.
    Bollands AD; Lowe KC
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1986; 85(2):309-12. PubMed ID: 2879690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
    Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of artificial blood substitute (fluosol-DA 20%) in patients of cerebral ischemia].
    Oda Y; Murata T; Uchida Y; Mori K; Nagasawa S; Naruo Y; Asato R; Handa H
    No Shinkei Geka; 1982 Jun; 10(6):637-44. PubMed ID: 7121730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation.
    Yang FS; Caldwell KD; Giddings JC; Astle L
    Anal Biochem; 1984 May; 138(2):488-94. PubMed ID: 6742424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of varying extents of Fluosol-DA or normal saline haemodilution on the dose dependent kinetics of phenytoin in the rat.
    Shrewsbury RP; Oliver SR; Lewis LM; Anderson WT; White LG
    J Pharm Pharmacol; 1989 Aug; 41(8):582-4. PubMed ID: 2571710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.